Loading...
•
Dec 31, 2025
Nuvectis Pharma Q4 2025 Earnings Report
Nuvectis Pharma reported increased operating expenses and a wider net loss for the fourth quarter of 2025, while strengthening its cash position year over year.
Key Takeaways
Nuvectis reported a net loss attributable to common shareholders of $28871000 for Q4 2025, with research and development expenses of $18153000 and general and administrative expenses of $9421000. Cash and cash equivalents increased to $31634000 as of December 31, 2025.
Net loss attributable to common shareholders was $28871000.
Research and development expenses totaled $18153000.
General and administrative expenses were $9421000.
Cash and cash equivalents increased to $31634000 year over year.
Forward Guidance
The company expects its current cash position to fund operations through multiple potential NXP900 Phase 1b milestones and into the second half of 2027.
Positive Outlook
- Cash runway expected into the second half of 2027.
- Ongoing Phase 1b enrollment for NXP900 monotherapy.
- Combination studies advancing in EGFR-mutated NSCLC.
- Potential multiple data readouts in 2026.
- Strengthened cash position following 2025 financing activities.
Challenges Ahead
- Continued operating losses expected.
- Increased R&D expenses year over year.
- Dependence on successful clinical trial outcomes.
- No revenue generation as a clinical-stage company.
- Potential dilution from future capital raises.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...